We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+0.28%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.95B
AUM Growth
-$468M
Cap. Flow
-$179M
Cap. Flow %
-6.06%
Top 10 Hldgs %
70.08%
Holding
59
New
4
Increased
11
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$58M
2
RVMD icon
Revolution Medicines
RVMD
+$35.5M
3
VERV
Verve Therapeutics
VERV
+$35.3M
4
XNCR icon
Xencor
XNCR
+$33.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$31.5M

Top Sells

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$102M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$58.2M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$44.7M
4
CGON icon
CG Oncology
CGON
+$37.5M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$37M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THRD
26
DELISTED
Third Harmonic Bio
THRD
$24.4M 0.83%
2,372,933
-1,993,000
-46% -$24.8M
KURA icon
27
Kura Oncology
KURA
$798M
$22.4M 0.76%
2,567,469
-804,292
-24% -$11.6M
ALLK
28
DELISTED
Allakos
ALLK
$20M 0.68%
16,552,417
– –
GLUE icon
29
Monte Rosa Therapeutics
GLUE
$1.35B
$19.2M 0.65%
+2,764,471
New +$20.7M
ITOS
30
DELISTED
iTeos Therapeutics
ITOS
$17.9M 0.61%
+2,325,000
New +$20M
EPIX
31
DELISTED
ESSA Pharma
EPIX
$15.7M 0.53%
8,748,629
– –
FDMT icon
32
4D Molecular Therapeutics
FDMT
$526M
$14.9M 0.5%
2,670,642
-4,712,000
-64% -$37M
RAPT
33
DELISTED
RAPT Therapeutics
RAPT
$14.6M 0.49%
+1,154,695
New +$14.7M
ENGN icon
34
enGene Therapeutics
ENGN
$117M
$14M 0.47%
2,106,037
-145,000
-6% -$1.13M
RPTX
35
DELISTED
Repare Therapeutics
RPTX
$13.5M 0.46%
10,333,600
– –
FBRX icon
36
Forte Biosciences
FBRX
$1.57B
$13.5M 0.46%
594,282
+475,000
+398% +$5.65M
VSTM icon
37
Verastem
VSTM
$496M
$10.9M 0.37%
2,100,468
+415,249
+25% +$1.64M
TCRX icon
38
TScan Therapeutics
TCRX
$48.4M
$9.09M 0.31%
2,989,474
– –
IMUX icon
39
Immunic
IMUX
$190M
$8.9M 0.3%
890,297
– –
PVLA
40
Palvella Therapeutics
PVLA
$2.04B
$8.36M 0.28%
696,555
+438,929
+170% +$6.89M
AVTX icon
41
Avalo Therapeutics
AVTX
$993M
$7.7M 0.26%
1,036,679
+69,679
+7% +$745K
IMA
42
ImageneBio Inc
IMA
$63.6M
$6.57M 0.22%
333,880
-63,550
-16% -$1.28M
MOLN
43
Molecular Partners
MOLN
$6.46M 0.22%
1,353,968
+910,747
+205% +$5.01M
CTMX icon
44
CytomX Therapeutics
CTMX
$686M
$5.39M 0.18%
5,228,461
– –
OVID icon
45
Ovid Therapeutics
OVID
$422M
$3.6M 0.12%
3,853,818
– –
SABS icon
46
SAB Biotherapeutics
SABS
$263M
$3.51M 0.12%
917,826
– –
VIGL
47
DELISTED
Vigil Neuroscience
VIGL
$3.08M 0.1%
1,813,633
– –
CBIO
48
Crescent Biopharma
CBIO
$525M
$2.38M 0.08%
95,443
– –
TENX icon
49
Tenax Therapeutics
TENX
$386M
$2.1M 0.07%
339,549
– –
ELEV
50
DELISTED
Elevation Oncology
ELEV
$1.67M 0.06%
2,966,836
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2024 Portfolio in Review

As of Q4 2024, BVF Inc held 59 positions worth $2.95B, down 14% from $3.42B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

BVF Inc withdrew a net $179M in Q4 2024, closing 6 positions and reducing 13 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $58.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in Septerna Inc worth $56.2M.

  • BVF Inc's largest Q4 2024 buy was Septerna Inc: 2,452,024 shares worth $56.2M.
  • BVF Inc added most to Revolution Medicines in Q4 2024, an estimated $35.5M increase.
  • BVF Inc's biggest Q4 2024 reduction was MoonLake Immunotherapeutics, cutting an estimated $102M.
  • BVF Inc fully exited Ionis Pharmaceuticals in Q4 2024, selling an estimated $58.2M.
  • BVF Inc's ten largest holdings make up 70% of its $2.95B portfolio in Q4 2024.
  • BVF Inc opened 4 new positions and closed 6 in Q4 2024.
  • BVF Inc's portfolio value fell 14% quarter-over-quarter to $2.95B.

Based on BVF Inc's 13F filing for Q4 2024, filed 14 Feb 2025.